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Clinical implications 33 
This study demonstrates the utility of intradermal testing to elucidate penicillin class cross-reactivity 34 
in patients with a history of severe presumed T-cell mediated hypersensitivity. The studysuggests 35 
patients should avoid not just the inciting penicillin, yet demonstrates tolerance of oral 36 
cephalosporins and utilization of alternative narrow spectrum beta-lactams 37 
 38 
To the Editor, 39 
 40 
Currently, a significant driver of Ig-E-mediated cross-reactivity between penicillins/cephalosporins is 41 
thought to be the R1 side chain, with contemporary cephalosporin cross-reactivity with penicillin 42 
allergy occurring at a rate of < 2% 1. However, the extent to which there is cross-reactivity between 43 
drugs within the penicillin class in patients with severe delayed and presumed T-cell mediated 44 
reactions is unknown.  45 
A prospective multicentre cohort study was performed at Austin Health and Peter MacCallum 46 
Cancer Centre in Melbourne Victoria, between 1st April 2015 and 24th February 2019. Study 47 
participants included patients referred for testing with a history of a severe T-cell mediated 48 
hypersensitivity associated with a penicillin.  A penicillin was defined as any drug within the penicillin 49 
class and in our cohort included:  penicillin VK, penicillin G, flucloxacillin, dicloxacillin, amoxicillin, 50 
amoxicillin-clavulanate, ampicillin or piperacillin-tazobactam.  51 
A severe T-cell mediated hypersensitivity syndrome was defined as drug reaction with eosinophilia 52 
and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP) or severe 53 
maculopapular exanthem (MPE). Patients experiencing Stevens-Johnson syndrome and toxic 54 
epidermal necrolysis (SJS/TEN) associated with a penicillin were excluded. For phenotypes of DRESS 55 
and AGEP, a RegiSCAR score of ≥ 4 (probable or definite) and an AGEP score of ≥ 2 respectively were 56 
required2, 3. Severe MPE was defined as an extensive cutaneous exanthem with more than 50% of 57 
body surface area and RegiSCAR score of 2-3 (possible)2.  All cases had at least one antibiotic that 58 
had been administered within 5 drug half-lives of onset of rash, a Naranjo score of ≥ 5, phenotype 59 
confirmed by dermatologist or histopathology, and had at least three investigations to exclude 60 
common alternative causes such as infections or autoimmune diseases. 61 
Both sites are tertiary referral testing centres with established drug and antibiotic allergy testing 62 
programs utilizing previously published in vivo (skin prick testing [SPT] and intradermal testing [IDT]) 63 
testing protocols including the highest non-irritating drug concentrations where possible4, 5. As 64 
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previously described, skin testing (SPT/IDT) and patch testing (PT) was performed no earlier than 6 65 
weeks following the resolution of cutaneous manifestations utilizing the previously published 66 
method4, 5. The routine IDT panel included: Normal Saline (0.9% solution), penicillin G (1000 IU/ml, 67 
10,000IU/ml), DAP-major (benzylpenicilloyl poly-L-lysine; final concentration 1.07 X10-2 mol/L), 68 
minor-determinate mixture (MDM; sodium benzylpenicillin, benzylpenicilloic acid, sodium 69 
benzylpenicilloate; 1.5 mg/mL; final concentration 1.5 mol/L), ampicillin (25mg/ml), flucloxacillin 70 
(2mg/ml), cefazolin (1mg/ml) and ceftriaxone (2.5mg/ml). Piperacillin-tazobactam (4.5mg/ml) IDT 71 
was performed in patients reporting a primary piperacillin-tazobactam allergy or were 72 
immunocompromised with a reported penicillin allergy. All test reagents (no excipients) were diluted 73 
in water or Normal Saline. Skin test positive was defined as per previous definitions, in brief a 74 
delayed IDT was considered positive when an infiltrated erythema with a diameter of greater than 75 
5mm was present as pre previous definition.5 Skin testing utilizing the aforementioned routine IDT 76 
panel was performed in 6 healthy controls and patients with a history of IgE mediated penicillin 77 
hypersensitivity (Supplementary Table E1). 78 
 79 
Peripheral blood mononuclear cells (PBMCs) were isolated from whole heparinised blood of patients 80 
at time of IDT. PBMCs were stored at -80○C in 90% heat-inactivated fetal bovine serum and 10% 81 
DMSO until IFN-γ release Enzyme Linked ImmunoSpot (ELISpot) assay and DNA extraction was 82 
performed as per previously published methods. 6 (Online Repository materials) Ethics approval was 83 
obtained from the Austin Health Research Ethics Committee (Approval 15/Austin/75). 84 
During the study period 724 patients completed SPT/IDT or PT for a suspected antibiotic allergy. 85 
Among the 724 patients, 1163 antibiotic allergy labels were reported (905 [77.8%] beta-lactam; 680 86 
[58.5%] penicillin). 602 patients (83%) reported penicillin-associated hypersensitivity, 216 with 87 
delayed hypersensitivity and 32 with a severe T-cell mediated hypersensitivity. Of these 32 patients 88 
with delayed and presumed T-cell mediated hypersensitivity, 14 (44%) were negative to all reagents, 89 
6 (19%) positive to ≤ 2 tested reagents (Supplementary Table E2) and 12 (38%) had a positive 90 
intradermal test documented to > 2 reagents from the routine IDT panel (Figure 1, Table 1).   91 
The patient phenotypes and characteristics of the 12 patients positive to > 2 intradermal test 92 
reagents are demonstrated in Table 1. Briefly, the phenotypes were DRESS (3/12; 25%), AGEP (3/12; 93 
25%) and severe MPE (6/12; 50%). The primary implicated penicillins were piperacillin-tazobactam 94 
(6, 50%); amoxicillin (4, 33%) and flucloxacillin (2, 17%). The median age was 52.5 years (IQR 36-48), 95 
50% (6/12) female, and 5 (41.6%) immunocompromised (solid organ transplant recipient, cancer, 96 
autoimmune/connective tissue disorder requiring immunomodulating therapy). The median time 97 
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between rash onset and intradermal testing and PBMC sampling was 395.5 days (IQR 195-1308). 98 
Positive reactions to IDT occurred as early as 6 hours post inoculation and all patients were positive 99 
by 24 hours with persistence of skin redness and induration for greater than 72 hours. No systemic 100 
adverse events to skin testing were reported. All patients were positive to tested IDT concentrations 101 
of ampicillin, penicillin G and flucloxacillin and negative to 0.9% N. saline, PPL (neat), MDM (neat), 102 
cefazolin and ceftriaxone (Figure 1). In patients with piperacillin-tazobactam as the primary 103 
implicated drug or immunocompromised, piperacillin-tazobactam IDT was performed and positive in 104 
all tested (8/8). A similar delayed pattern was not observed in healthy controls or in 255 patients 105 
with immediate IgE mediated hypersensitivity reactions to penicillins (Supplementary Table E1).  106 
Eleven of 12 (92%) patients tolerated an oral 1st or 2nd generation cephalosporin provocation after 107 
IDT (Table 1). One remaining patient has yet to undergo oral provocation. Five of 12 (41.6%) patients 108 
were positive to the primary implicated drug on IFN-γ ELISpot testing (Supplementary Figure E1).  109 
 110 
We provide evidence for apparent cross-reactivity within penicillin class drugs by demonstrating 111 
penicillin IDT cross-reactivity in patients reporting a penicillin-associated severe T-cell mediated 112 
hypersensitivity.  The vast majority of these patients subsequently tolerated oral cephalosporins.  113 
Prior studies have previously demonstrated cross-reactivity between R1-side chains of 114 
aminopenicillins (amoxicillin, ampicillin, amoxicillin-clavulanate) and aminocephalosporins (cefalexin, 115 
cefaclor, cefadroxil, cefprozil, cefatrizine, cefonicid, cefmandole) in delayed (T-cell-mediated) 116 
hypersensitivity, and the absence of cross-reactivity with non-cross reactive cephalosporins, 117 
carbapenems and monobactams.7, 8Romano et al.  in a cohort of 214 intradermal test positive 118 
patients reporting a penicillin T-cell-mediated hypersensitivity (8 with SCAR), 89 (42%) of patients 119 
were positive to benzylpenicillin, ampicillin and amoxicillin and only 8 (8.9%) also positive to the 120 
MDM or PPL, supporting the cross-reactivity pattern seen in our cohort of all severe T-cell mediated 121 
hypersensitivity7 .  Overall, cross-reactivity patterns in severe T-cell-mediated hypersensitivities have 122 
not been well-defined due to caution in performing IDT and patch testing in this population, the 123 
incomplete sensitivity and lack of widespread availability and validation of ex vivo and in vitro 124 
methods, and the inability to use oral ingestion challenge as the gold standard. Watts et al. 125 
previously described a single case of Penicillin G DRESS with IDT and PT positivity to both Penicillin G 126 
and amoxicillin,9 and similar to our cohort, the patient tolerated an oral cephalosporin. This finding 127 
may be under reported in the literature due to the prior general avoidance of performing IDT in 128 
patients reporting a severe T-cell mediated hypersensitivity.  The pattern of cross-reactivity 129 
demonstrated in our study and tolerance of similar R1 side-chain containing oral cephalosporins 130 
points towards the “penicillin ring” (thiazolidine) being an important component in generation of the 131 
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primary antigen. Further, it highlights the importance of testing alternative penicillins in addition to 132 
PPL and MDM which were not useful reagents in documenting cross-reactivity between penicillins in 133 
patients with DRESS, AGEP and severe-MPE. We believe these are important lessons for skin testing 134 
in severe delayed and presumed T-cell mediated hypersensitivity and predicting beta-lactam 135 
tolerability in these patients.  136 
 137 
Although a limitation to our findings includes a lack of confirmation of identified penicillin cross-138 
reactivity with ingestion challenge, this would not be considered an ethical approach given the 139 
severity of the reported reactions and the presence of alternative therapeutic agents in these 140 
patients. Although, false positive reactions are possible, the absence of similar results in controls 141 
(Online Repository materials), reproducibility of the positive phenotypes on IDT and confirmatory 142 
patch testing with varied drug formulation (patient 1), are all supportive of true T-cell mediated 143 
responses. The dose-dependency of responses in the skin is in keeping with T-cell mediated 144 
responses where non-covalent binding of the drug or drug-altered peptide occurs in a concentration 145 
dependent fashion with an immune receptor. This could explain the positive responses we have 146 
seen with benzyl penicillin used at 1000 IU/mL and 10,000 IU/mL whereas MDM with a 0.5 mg/ml 147 
benzyl penicillin was consistently negative.   The apparent lack of sensitivity of IFN-γ release ELISpot 148 
positivity to all penicillins is also noted, however this may reflect the variable sensitivity of the assay 149 
or that IFN-γ is not the relevant cytokine output for the phenotypes of delayed reactions tested . 150 
Further, the absence of IFN-γ positivity in all skin test positive patients may reflect the known 151 
absence of circulating drug-reactive effector memory T-cells despite durable long-lasting tissue-152 
resident memory T cells responses being evident in vivo.10  This work confirms a previously 153 
infrequently described pattern of cross-reactivity between penicillins in severe T-cell mediated 154 
penicillin hypersensitivity and provides support for cephalosporin tolerability in these populations. 155 
Future work needs to be directed at understanding the antigenic structures and genomic predictors 156 
in these severe penicillin-associated T-cell mediated hypersensitivities.  157 
 158 
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Figure 1 192 
 193 
Figure 1 Abbreviations; PPL, DAP-major (benzylpenicilloyl poly-L-lysine; final concentration 1.07 X10-194 
2 mol/L), MDM, minor-determinate (sodium benzylpenicillin, benzylpenicilloic acid, sodium 195 
benzylpenicilloate), Penicillin G†, Penicillin G 1000 IU/mL;  PenicillinG ‡, Penicillin G 10000 IU/mL. 196 
Figure 1: Legend: Pictorial representation of patients reporting penicillin-associated severe T-cell 197 
mediated hypersensitivity from tested cohort. Pustular exanthem of a patient with flucloxacillin-198 
associated AGEP [Patient 11] (A-B) with corresponding histopathology demonstrating pustule 199 
formation (upper arrow) and upper dermal edema (lower arrow) (low power x10 magnification; 200 
upper image) and spongiosis and neutrophil migrating through epidermis [arrow] (high power x100 201 
magnification; lower image) (C). Intradermal testing 24 hours post inoculation showing widespread 202 
penicillin cross-reactivity (pustule formation noted on penicillin 10mg/ml IDT) (D).  Further patients 203 
with identical pattern of intradermal test cross-reactivity demonstrated in (E [Patient 4], F [Patient 204 
9], G [Patient 1]). Please note that a bruise is noted in Patient E where the Normal Saline was 205 
inoculated. Panel H illustrates a Grade 3 positive patch test result from same patient with IDT 206 
demonstrated in Panel G (PT performed 6 months following positive IDT) [Patient 1]. Patient 1 IDT 207 
was performed with amoxicillin in addition to the standard panel (Panel G) to correlated with patch 208 
testing performed to amoxicillin (Panel H). 209 
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Table 1: Patients with penicillin-associated severe T-cell-mediated hypersensitivity with positive intradermal testing 
No. Sex/ 
Age 
Pre-existing skin disease 


























≤ 24 hours No Cephalexin 
2 51F Nil DRESS 4 Yes Piperacillin-
tazobactam 
473 AMP, FLU, 
PEN, PIP-
TAZ 
≤ 24 hours No Cefuroxime 
3 38F Diabetes mellitus DRESS 7 Yes Piperacillin-
tazobactam 
312 AMP, FLU, 
PEN, PIP-
TAZ 
≤ 24 hours PIP-TAZ Cefuroxime 
4 42F Hairy cell leukemia MPE 2 No Piperacillin-
tazobactam  
269 AMP, FLU, 
PEN, PIP-
TAZ 
≤ 24 hours No
#
 Cephalexin 
5 45F Chronic myelocytic leukemia MPE 2 No Piperacillin-
tazobactam  
318 AMP, FLU, 
PEN, PIP-
TAZ 
≤ 24 hours No
#
 Cefuroxime 
6 64M Liver transplant recipient for 
alcoholic liver disease 
MPE 2 Not performed Amoxicillin 1470 AMP, FLU, 
PEN, PIP-
TAZ 
≤ 24 hours AMP Cephalexin 
7 38F Metastatic melanoma^^ MPE 3 Yes Amoxicillin 121 AMP, FLU, 
PEN, PIP-
TAZ 
≤ 24 hours AMP Cefuroxime 
8 34M Hairy cell leukemia MPE 2 Not performed Piperacillin-
tazobactam  
1146 AMP, FLU, 
PEN, PIP-
TAZ 
≤ 24 hours No Cefuroxime 




≤ 24 hours No Cephalexin 
10 62M Follicular lymphoma DRESS 4 Yes Piperacillin-
tazobactam 
1078 AMP, FLU, 
PEN, PIP-
TAZ 
≤ 24 hours PIP-TAZ Cephalexin 




≤ 24 hours No Cephalexin 








 Abbreviations: F; female; M, male; DRESS, drug reaction with eosinophilia and systemic symptoms; AGEP, acute generalized exanthematous pustulosis; MPE, severe 
maculopapular exanthem; PT, patch testing; IDT, intradermal testing; AMX, amoxicillin; AMP, ampicillin; PEN, Penicillin G, FLU, flucloxacillin; PIP-TAZ, piperacillin-
tazobactam; OP, oral provocation; pip-tazo, piperacillin-tazobactam. 
⁞ 
RegiSCAR score as per published definitions (<2, no DRESS; 2-3, possible DRESS; 4-5, probable DRESS; ≥ 6 definite DRESS)
2
 
*Haemotoxylin and Eosin (H & E) performed as per routine clinical practice 
** Tested IDT concentrations; Ampicillin 25mg/ml, benzylpenicillin 1mg/ml, benzylpenicillin 10mg/ml, flucloxacillin 2mg/ml, piperacillin-tazobactam 4.5mg/ml (amoxicillin 
20mg/ml utilized only for Patient 1) 
†
Latency period – time (days) from rash onset to intradermal testing. If year only known, date default 1
st
 of January of implicated year.  
‡ 
Reproduced with patch testing to ampicillin 10%, benzylpenicillin 10%. Performed 6386 days post index reaction - 6 months following positive IDT test. 
^ Piperacillin-tazobactam not tested
10 
 
^^melanoma patient on check-point inhibitor 
#
 Poor CD3 response reflecting recent cladribine (660) and cytarabine (859) chemotherapy 





Online Repository Materials –  
Cross-reactivity between penicillins in severe T-cell-mediated penicillin hypersensitivity 
 
Supplementary Methods: IFN-γ release in response to overnight incubation with implicated 
antibiotic(s) was performed by Enzyme Linked ImmunoSpot (ELISpot) assay in triplicate from thawed 
PBMCs (rested overnight) as previously described 
E1
. PBMCs (200,000 cells per well) were incubated 
with investigated drugs at concentrations representative of peak serum concentrations (Cmax) and a 
level 10-fold higher than Cmax 
E2
. Testing was also performed with a negative (unstimulated) and 
positive control (anti-CD3 antibody Mabtech, Victoria, Australia) in duplicate and healthy control 
(penicillin exposed non-allergic) for all testing antibiotic concentrations. The mean number of spots 
for the test and unstimulated wells were calculated. A positive response was defined as greater than 
50 spot forming units (SFU)/million cells after background (unstimulated control) removal as per 
previously published definitions 
E1, E3




Table E1 – Clinical characteristics and testing results of tested health controls and penicillin IgE-
mediated controls 
Patient characteristics Healthy controls  
(n = 6) 
Penicillin IgE-mediated*  
(n = 255) 
Tested cohort Outpatients; 1
st
 Jan – 10
th
 Sept 2019 Outpatients; 1
st
 April 2015 – 24
th
 Feb 2019 
Age (years), median [IQR] 44 (40,47) 58 (46, 70) 
Sex (female) 4 (66.67) 158 (61.96) 
Prior non-antibiotic allergy 2 (33.33) ND 
Prior antibiotic allergy 1 (16.67) 255 (100) 
Penicillin allergy history 
       Immediate (IgE mediated) 
       Delayed (T-cell-mediated) 
0 (0) 255 (100) 
    255 (100) 
    0 (0) 
Any positive penicillin skin testing 0 (0) 25 (9.8) 
Immediate positive skin prick† or 
intradermal testing ‡ 
       >2 penicillin testing reagents 
       PEN, AMP, FLU (no MDM or PPL) 
0 (0)  
 
13 (5)  
1 (0.3) 
Delayed positive skin prick testing† 0 (0) 0 (0) 
Delayed positive intradermal testing‡ 0 (0) 0 (0) 
Abbreviations; IQR, interquartile range; ND, no data; PEN, penicillin G; AMP, ampicillin; MDM, minor determinant mixture; 
PPL, (DAP-Major; benzylpenicilloyl poly-L-lysine), FLU, flucloxacillin 
*Patients reporting a penicillin immediate (IgE-mediated) hypersensitivity (e.g. urticaria, angioedema, anaphylaxis) that 
underwent skin prick and intradermal testing during the study period. 
† Standard Skin Testing Panel: Histamine, Normal Saline (0.9% solution), Penicillin G (10,000IU/mL), DAP-major 
(benzylpenicilloyl poly-L-lysine; final concentration 1.07 X10
-2
 mol/L), minor-determinate mixture (MDM; sodium 
benzylpenicillin, benzylpenicilloic acid, sodium benzylpenicilloate; 1.5 mg/mL; final concentration 1.5 mol/L), ampicillin 
(25mg/ml). All drugs are the same as those utilized in test patients and are diluted in water or Normal Saline. 
‡ Standard Intradermal Testing Panel: Normal Saline (0.9% solution), Penicillin G (1000 IU/mL, 10,000IU/mL), DAP-major 
(benzylpenicilloyl poly-L-lysine; final concentration 1.07 X10
-2
 mol/L), minor-determinate mixture (MDM; sodium 
benzylpenicillin, benzylpenicilloic acid, sodium benzylpenicilloate; 1.5 mg/mL; final concentration 1.5 mol/L), ampicillin 
(25mg/ml), flucloxacillin (2mg/ml), cefazolin (1mg/ml) and ceftriaxone (2.5mg/ml). All drugs are the same as those utilized 




Table E2 – Positive skin testing results of penicillin-associated severe T-cell mediated hypersensitivity with ≤ 2 positive intradermal tests 
No. Sex/ 
Age 
Pre-existing skin disease 





















1 59F Nil DRESS 4 Yes Amoxicillin 310 AMP, PPL ≤ 24 hours AMP Not performed 
2 75M Chronic inflammatory 
demyelinating 
polyneuropathy 





≤ 24 hours No Cephalexin 
3 55F Asplenia  MPE 2 Not performed Amoxicillin clavulanate 1057 CLAV ≤ 24 hours CLAV Cefuroxime, 
penicillin VK 
4 70M Chronic lymphocytic 
leukemia 
MPE 3 Not performed Amoxicillin clavulanate  57 CLAV ≤ 24 hours No Cefuroxime, 
amoxicillin, 
penicillin VK 
5 70F Chronic lymphocytic 
leukemia 
MPE 2 Not performed Amoxicillin  1346 AMP, 
AMX 
≤ 24 hours No Cefuroxime, 
penicillin VK 
6 59M Psoarsis MPE 2 Not performed Penicillin unspecified 6163 AMP, 
AMX 
≤ 24 hours AMP Cefuroxime, 
penicillin VK 
 
Abbreviations: F; female; M, male; DRESS, drug reaction with eosinophilia and systemic symptoms; AGEP, acute generalized exanthematous pustulosis; MPE, severe 
maculopapular exanthem; PT, patch testing; IDT, intradermal testing; AMX, amoxicillin; AMP, ampicillin; PEN, Penicillin G, FLU, flucloxacillin; PIP-TAZ, piperacillin-
tazobactam; OP, oral provocation; pip-tazo, piperacillin-tazobactam; CLAV, clavulanate; PPL, DAP-major determinant. 
⁞ 
RegiSCAR score as per published definitions (<2, no DRESS; 2-3, possible DRESS; 4-5, probable DRESS; ≥ 6 definite DRESS)
4
 
*Haemotoxylin and Eosin (H & E) performed as per routine clinical practice 
** Tested IDT concentrations; Ampicillin 25mg/ml, benzylpenicillin 1mg/ml, benzylpenicillin 10mg/ml, flucloxacillin 2mg/ml, piperacillin-tazobactam 4.5mg/ml (patient 2 
only), amoxicillin 20mg/ml (Patient 5 & 6 only), clavulanate 5mg and 20mg/ml [in patients 3 and 4 negative to routine panel]) 
†
Latency period – time (days) from rash onset to intradermal testing. If year only known, date default 1
st
 of January of implicated year.  
 
Supplementary Figure E1: IFN-γ release Enzyme Linked ImmunoSpot (ELISpot) assay results for 
tested cohort. 
 
Legend: IFN-γ release Enzyme Linked ImmunoSpot (ELISpot) Assay were performed on blood 
samples taken from all patients. The mean number of spots for the test and unstimulated wells were 
calculated. A positive response was defined as greater than 50 spot-forming units (SFU)/million cells 
after background (unstimulated control) removal (dotted line). Each dot point represents a different 
drug/drug-concentration. All drugs were tested at µg/ml concentrations. 
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